Testing Experimental Pancreatic Cancer Treatment
common.study.values.description
“Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers”
This pilot clinical trial studies the use of integrin alpha-v-beta [18F]-R01-MG-F2 Positron Emission Tomography/Computed Tomography (PET/CT) and Positron Emission Tomography-Magnetic Resonance Imaging in (PET/MRI) in measuring response in patients with pancreatic cancer and healthy volunteers. Integrins, such as integrin alpha-v-beta-6 (avb6), are a family of membrane receptors that are overexpressed on the cell surface of pancreatic cancers. [18F]-R01-MG-F2 targets avb6, which may improve early detection of and better stratify treatment options for patients with pancreatic cancer.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Diagnostic Test - Computed Tomography
Undergo CT scan
Laboratory Biomarker Analysis
Correlative studies
Diagnostic Test - PET/MRI scan
Undergo PET/MRI scan
Drug - [18F]FP-R01-MG-F2
radioactive tracer
participant.views.study.view.additional
participant.views.study.view.scientific-title
Detection of Integrin Alpha-v-Beta 6 in Pancreatic Cancer With [18F]-R01-MG-F2: a First in Human Study
common.study.values.clinical-trial-id
NCT02683824
participant.views.study.view.id
pen6pe
